



16 November 2020

ASX Announcement

NEUROSCIENTIFIC COMPLETES STRATEGIC PLACEMENT TO ALPHASWISS PARTNERS

Perth Australia, 16 November 2020: Neuroscientific Biopharmaceuticals Limited (ASX: NSB) (**NeuroScientific** or the **Company**) is pleased to advise that further to the announcement on 11 November 2020 regarding the placement of shares to AlphaSwiss Partners SA to raise \$2.4 million (**Placement**), the Placement shares have been allocated and will be issued today.

In addition to the Placement shares, the Company today has also allocated the unlisted options to Westar Capital Limited, as announced on 11 November 2020.

Following this announcement, the Company will release the Appendix 2A to detail the issue of the above securities.

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddel
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Nonexecutive Chairman
bl@neuroscientific.com
+61 412 281 780